AstraZeneca: Diabetes Mellitus, Type 2 trials

The registry lists 345 Diabetes Mellitus, Type 2 studies with AstraZeneca as lead sponsor. 13 are open to participants now and 149 have results posted.

Phase 1 89Phase 2 47Phase 3 122Phase 4 28No phase 65(a study in two phases counts in both)

Studies

Page 4 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 DiabetesCompletedNCT00382239Phase 2
• Safety and Efficacy of Exenatide as MonotherapyCompletedNCT00381342Phase 3
• Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 DiabetesCompletedNCT00359879Phase 3
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and MetforminCompletedNCT00324363Phase 3
• GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 DiabetesTerminatedNCT00300105Phase 3
• GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 DiabetesCompletedNCT00280865Phase 2
• ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin SensitivityTerminatedNCT00263965Phase 2
• A Trial of BMS-512148 in Patients With Type 2 Diabetes MellitusCompletedNCT00263276Phase 2
• C-Reactive Protein (CRP) in Obese Diabetic WomenCompletedNCT00262548Phase 4
• Dose Response Study in Japanese PatientsTerminatedNCT00261417Phase 2
• GALLANT 14 Tesaglitazar vs. Metformin and FenofibrateTerminatedNCT00261352Phase 3
• G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)TerminatedNCT00255645
• GALLANT 4 Tesaglitazar vs. GlibenclamideTerminatedNCT00255541Phase 3
• The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy FemalesCompletedNCT00254800Phase 1
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes MellitusCompletedNCT00254254Phase 2
• GALLEX 1 - Long Term Extension Study in Patients With Type 2 DiabetesTerminatedNCT00252876Phase 3
• GALLANT 22 Tesaglitazar vs. PlaceboTerminatedNCT00252837Phase 3
• GALLANT 2 Tesaglitazar vs. PlaceboTerminatedNCT00252772Phase 3
• GALLANT 8 Tesaglitazar Add-on to MetforminTerminatedNCT00251953Phase 3
• GALLANT 7 Tesaglitazar Add-on to SulphonylureaTerminatedNCT00251940Phase 3
• GALLANT 9 Tesaglitazar vs. Placebo in Combination With InsulinTerminatedNCT00242372Phase 3
• Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 DiabetesCompletedNCT00241423Phase 2
• A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 DiabetesCompletedNCT00240253Phase 4
• DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European GuidelinesCompletedNCT00233649
• GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 DiabetesTerminatedNCT00229710Phase 3
• ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)TerminatedNCT00229684Phase 2
• GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes MellitusTerminatedNCT00226330Phase 3
• GALLANT 5 Tesaglitazar Versus MetforminTerminatedNCT00214591Phase 3
• GALLANT 6 Tesaglitazar vs. PioglitazoneTerminatedNCT00214565Phase 3
• A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic SubjectsCompletedNCT00162305Phase 2
• Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 DiabetesCompletedNCT00111540Phase 3
• Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusCompletedNCT00108004Phase 3
• Study Examining Exenatide Long-Acting Release in Subjects With Type 2 DiabetesCompletedNCT00103935Phase 2
• Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyCompletedNCT00099619Phase 3
• Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic AgentsCompletedNCT00099333Phase 2
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and MetforminCompletedNCT00099320Phase 3
• Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00085969Phase 2
• Evaluation of an Orally Administered Medication When Taken in Conjunction With PramlintideCompletedNCT00044707Phase 2
• Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes MellitusCompletedNCT00044694Phase 2
• Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea CombinationCompletedNCT00044668Phase 3
• Evaluation of the Effect of Pramlintide on Satiety and Food IntakeCompletedNCT00042601Phase 2
• Evaluation of the Bioavailability of PramlintideCompletedNCT00042471Phase 2
• Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a SulfonylureaCompletedNCT00039026Phase 3
• Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With MetforminCompletedNCT00039013Phase 3
• Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes MellitusCompletedNCT00035984Phase 3